Abstract
Bile acids are essential for food digestion and nutrient absorption, but also act as signalling molecules involved in hepatobiliary diseases, gastrointestinal disorders and carcinogenesis. While many studies have focused on the genetic determinants of blood metabolites, research focusing specifically on genetic regulation of bile acids in the general population is currently lacking. Here we investigate the genetic architecture of primary and secondary bile acids in blood plasma, reporting associations with both common and rare variants. By performing genome-wide association analysis (GWAS) of plasma blood levels of 18 bile acids (N = 4923) we identify two significantly associated loci, a common variant mapping to SLCO1B1 (encoding a liver bilirubin and drug transporter) and a rare variant in PRKG1 (encoding soluble cyclic GMP-dependent protein kinase). For these loci, in the sex-stratified GWAS (N♂ = 820, N♀ = 1088), we observe sex-specific effects (SLCO1B1 β ♂ = -0.51, P = 2.30×10−13, β♀ = -0.3, P = 9.90×10−07; PRKG1 β ♂ = -0.18, P = 1.80×10−01, β ♀ = -0.79, P = 8.30×10−11), corroborating the contribution of sex to bile acid variability. Using gene-based aggregate tests and whole exome sequencing, we identify rare pLoF and missense variants potentially associated with bile acid levels in 3 genes (OR1G1, SART1 and SORCS2), some of which have been linked with liver diseases.
Competing Interest Statement
G.T. and A.R.S. are full-time employees of Regeneron Genetics Center and receive salary, stock and stock options as compensation. L.K. is an employee of Humanity Inc., a company developing direct-to-consumer measures of biological ageing. All other authors declare no competing interests.
Funding Statement
The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), a Royal Society URF to J.F.W., the MRC Human Genetics Unit quinquennial programme QTL in Health and Disease, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions were performed at the Edinburgh Clinical Research Facility, University of Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. The CROATIA-VIS study in the Croatian island of Vis was supported through the grants from the Medical Research Council UK and Ministry of Science, Education and Sport of the Republic of Croatia (number 108‐1080315‐0302). The authors collectively thank a large number of individuals for their individual help in organising, planning and carrying out the field work related to the project and data management: Professor Pavao Rudan and the staff of the Institute for Anthropological Research in Zagreb, Croatia (organisation of the field work, anthropometric and physiological measurements, and DNA extraction); Professor Ariana Vorko‐Jovic and the staff and medical students of the Andrija Stampar School of Public Health of the Faculty of Medicine, University of Zagreb, Croatia (questionnaires, genealogical reconstruction and data entry); Dr Branka Salzer from the biochemistry lab Salzer, Croatia (measurements of biochemical traits); local general practitioners and nurses (recruitment and communication with the study population); and the employees of several other Croatian institutions who participated in the field work, including but not limited to the University of Rijeka and Split, Croatia; Croatian Institute of Public Health; Institutes of Public Health in Split and Dubrovnik, Croatia. SNP Genotyping of the Vis samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh.The MICROS (Micro-Isolates in South Tyrol) study is part of the genomic health care program 'GenNova' and was carried out in three villages of the Val Venosta on the populations of Stelvio, Vallelunga and Martello. We thank the primary care practitioners Raffaela Stocker, Stefan Waldner, Toni Pizzecco, Josef Plangger, Ugo Marcadent and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano and the South Tyrolean Sparkasse Foundation. The Northern Swedish Population Health Study (NSPHS) was funded by the Swedish Medical Research Council (project number K2007-66X-20270-01-3), and the Foundation for Strategic Research (SSF). The NSPHS as part of EUROSPAN (European Special Populations Research Network) was also supported by European Commission FP6 STRP grant number 01947 (LSHGCT-2006-01947). This work was also supported by the Swedish Society for Medical Research (AJ). The authors are grateful for the contribution of district nurse Svea Hennix for data collection and Inger Jonasson for logistics and coordination of the health survey. Finally, the authors thank all the community participants for their interest and willingness to contribute to the study The Erasmus Rucphen Family (ERF) study was supported by grants from The Netherlands Organisation for Scientific Research (NWO), Erasmus MC, the Centre for Medical Systems Biology (CMSB) and the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE Consortium, grant agreement HEALTH-F4-2007- 201413. We are grateful to all general practitioners for their contributions, Cornelia van Duijn and Ben Oostra for setting-up the ERF study, Petra Veraart for sorting out the genealogy records, Jeannette Vergeer and Peter Snijders for help in retrieving the materials needed to analyse data. We acknowledge support from the European Union's Horizon 2020 research and innovation programme IMforFUTURE (A.L.: H2020-MSCA-ITN/721815); the RCUK Innovation Fellowship from the National Productivity Investment Fund (L.K.: MR/R026408/1) and the MRC Human Genetics Unit programme grant, "QTL in Health and Disease" (J.F.W. and C.H.: MC_UU_00007/10).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were approved by local research ethics committees and all participants have given written informed consent. The ORCADES study was approved by the NHS Orkney Research Ethics Committee and the North of Scotland Research Ethics Committee. The CROATIA-Vis study was approved by the ethics committee of the medical faculty in Zagreb and the Multi-Centre Research Ethics Committee for Scotland. The Northern Swedish Population Health Study (NSPHS) was approved by the local ethics committee at the University of Uppsala (Regionala Etikprovningsnamnden, Uppsala). The MICROS study was approved by the ethical committee of the Autonomous Province of Bolzano, Italy. The ERF study was approved by the Erasmus institutional medical-ethics committee in Rotterdam, The Netherlands.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The full summary statistics from GWAS meta-analysis of bile acids will be uploaded to the University of Edinburgh Datashare repository and to GWAS catalog upon manuscript acceptance. There is neither Research Ethics Committee approval, nor consent from individual participants, to permit open release of the individual level research data underlying this study. The datasets analysed during the current study are therefore not publicly available. Instead, the research data and/or DNA samples for the ORCADES study are available from accessQTL@ed.ac.uk on reasonable request, following approval by the QTL Data Access Committee and in line with the consent given by participants. Each approved project is subject to a data or materials transfer agreement (D/MTA) or commercial contract. The summary statistics for complex traits and diseases (full list reported in Supplementary Table 5) are available in the IEU Open GWAS database https://gwas.mrcieu.ac.uk/.